IN2015DN03998A - - Google Patents
Info
- Publication number
- IN2015DN03998A IN2015DN03998A IN3998DEN2015A IN2015DN03998A IN 2015DN03998 A IN2015DN03998 A IN 2015DN03998A IN 3998DEN2015 A IN3998DEN2015 A IN 3998DEN2015A IN 2015DN03998 A IN2015DN03998 A IN 2015DN03998A
- Authority
- IN
- India
- Prior art keywords
- medicaments
- medicament
- substituents
- salt
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Abstract
The invention relates to compound of the formula (I); or a salt thereof wherein the substituents are as defined in the specification; to its preparation to its use as medicament and to medicaments comprising it.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261736748P | 2012-12-13 | 2012-12-13 | |
| PCT/IB2013/060859 WO2014091446A1 (en) | 2012-12-13 | 2013-12-12 | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03998A true IN2015DN03998A (en) | 2015-10-02 |
Family
ID=50030361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3998DEN2015 IN2015DN03998A (en) | 2012-12-13 | 2013-12-12 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9649314B2 (en) |
| EP (1) | EP2931282B1 (en) |
| JP (1) | JP6076498B2 (en) |
| KR (1) | KR101760586B1 (en) |
| CN (2) | CN107569487A (en) |
| AP (1) | AP2015008441A0 (en) |
| AU (1) | AU2013358591B2 (en) |
| BR (1) | BR112015013535A2 (en) |
| CA (1) | CA2890692A1 (en) |
| CL (1) | CL2015001610A1 (en) |
| CR (1) | CR20150314A (en) |
| CU (1) | CU20150061A7 (en) |
| EA (1) | EA028673B1 (en) |
| ES (1) | ES2709034T3 (en) |
| HK (1) | HK1209637A1 (en) |
| IL (1) | IL239244A0 (en) |
| IN (1) | IN2015DN03998A (en) |
| MA (1) | MA38157A1 (en) |
| MX (1) | MX363437B (en) |
| PE (1) | PE20151062A1 (en) |
| PH (1) | PH12015501216A1 (en) |
| SG (1) | SG11201503684WA (en) |
| TN (1) | TN2015000262A1 (en) |
| WO (1) | WO2014091446A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2890692A1 (en) | 2012-12-13 | 2014-06-19 | Novartis Ag | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors |
| EP3152207B1 (en) * | 2014-06-03 | 2019-05-08 | Novartis AG | Pyridopyrimidinedione derivatives as suppressors of non-sens mutations |
| JP6560257B2 (en) * | 2014-06-03 | 2019-08-14 | ノバルティス アーゲー | Pyrimido [4,5-b] quinoline-4,5 (3H, 10H) -dione derivative |
| US10138232B2 (en) * | 2014-06-03 | 2018-11-27 | Novartis Ag | Naphthyridinedione derivatives |
| CN109152747A (en) * | 2016-04-15 | 2019-01-04 | Uab研究基金会 | For stimulating the method readed over and compound of Premature stop codon |
| EP3762383B1 (en) * | 2018-03-06 | 2023-12-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Positive allosteric modulators of dopamine 1 receptor and method of use thereof |
| WO2019225625A1 (en) * | 2018-05-23 | 2019-11-28 | 京都薬品工業株式会社 | Readthrough inducer and pharmaceutical use thereof |
| EP4211171A2 (en) | 2020-09-10 | 2023-07-19 | Precirix N.V. | Antibody fragment against fap |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2884170B2 (en) | 1989-08-24 | 1999-04-19 | 株式会社フジモト・ブラザーズ | Anticancer agent containing 5-deazaflavin compound as active ingredient |
| WO1996028444A1 (en) * | 1995-03-15 | 1996-09-19 | Pfizer Inc. | 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| WO2004006906A2 (en) | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP4101846B1 (en) | 2003-04-11 | 2023-08-02 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| WO2007113841A2 (en) | 2006-04-03 | 2007-10-11 | Technion Research & Development Foundation Ltd. | Novel aminoglycosides and uses thereof in the treatment of genetic disorders |
| JP2010501571A (en) | 2006-08-23 | 2010-01-21 | ニューロジェン・コーポレーション | Haloalkyl-substituted pyrimidinone derivatives |
| JP2011507910A (en) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | Methods for changing the lifetime of eukaryotes |
| EP2422817A1 (en) | 2010-07-29 | 2012-02-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flavin-nucleic acid ligand conjugates |
| JP5877200B2 (en) * | 2010-08-05 | 2016-03-02 | ユニヴェルシテ ドゥ ドロワ エ サンテ ドゥ リール | Compounds useful for the treatment of diseases caused by nonsense mutations and pharmaceutical compositions containing the compounds |
| CA2890692A1 (en) | 2012-12-13 | 2014-06-19 | Novartis Ag | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors |
-
2013
- 2013-12-12 CA CA2890692A patent/CA2890692A1/en not_active Abandoned
- 2013-12-12 PE PE2015000911A patent/PE20151062A1/en not_active Application Discontinuation
- 2013-12-12 IN IN3998DEN2015 patent/IN2015DN03998A/en unknown
- 2013-12-12 EP EP13826612.7A patent/EP2931282B1/en active Active
- 2013-12-12 AU AU2013358591A patent/AU2013358591B2/en not_active Ceased
- 2013-12-12 AP AP2015008441A patent/AP2015008441A0/en unknown
- 2013-12-12 US US14/652,102 patent/US9649314B2/en not_active Expired - Fee Related
- 2013-12-12 WO PCT/IB2013/060859 patent/WO2014091446A1/en active Application Filing
- 2013-12-12 KR KR1020157018231A patent/KR101760586B1/en active IP Right Grant
- 2013-12-12 SG SG11201503684WA patent/SG11201503684WA/en unknown
- 2013-12-12 CN CN201710826258.0A patent/CN107569487A/en active Pending
- 2013-12-12 EA EA201591105A patent/EA028673B1/en not_active IP Right Cessation
- 2013-12-12 BR BR112015013535A patent/BR112015013535A2/en not_active Application Discontinuation
- 2013-12-12 ES ES13826612T patent/ES2709034T3/en active Active
- 2013-12-12 CN CN201380064035.5A patent/CN104837490B/en not_active Expired - Fee Related
- 2013-12-12 MX MX2015007562A patent/MX363437B/en unknown
- 2013-12-12 JP JP2015547244A patent/JP6076498B2/en not_active Expired - Fee Related
-
2015
- 2015-05-29 PH PH12015501216A patent/PH12015501216A1/en unknown
- 2015-06-04 IL IL239244A patent/IL239244A0/en unknown
- 2015-06-05 MA MA38157A patent/MA38157A1/en unknown
- 2015-06-09 TN TNP2015000262A patent/TN2015000262A1/en unknown
- 2015-06-10 CL CL2015001610A patent/CL2015001610A1/en unknown
- 2015-06-12 CU CUP2015000061A patent/CU20150061A7/en unknown
- 2015-06-12 CR CR20150314A patent/CR20150314A/en unknown
- 2015-10-23 HK HK15110447.1A patent/HK1209637A1/en unknown
-
2017
- 2017-04-04 US US15/478,778 patent/US20170266189A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03998A (en) | ||
| MX2015008627A (en) | Boronic acid derivatives and therapeutic uses thereof. | |
| NZ608116A (en) | Triazine-oxadiazoles | |
| IN2014DN10449A (en) | ||
| UA116648C2 (en) | FUMARATS AS A PRODUCT AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES | |
| PH12015501083A1 (en) | Novel pyridine derivatives | |
| MX2014009757A (en) | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy. | |
| MX343706B (en) | Novel heterocyclic derivatives. | |
| PH12015501843A1 (en) | Novel pyrazol derivatives | |
| MD20140072A2 (en) | New pyrrole compounds, process for their preparation and pharmaceutical compositions containing them | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| IN2015DN01119A (en) | ||
| IN2014DN01629A (en) | ||
| PH12018501709A1 (en) | Naphthridinedione derivatives | |
| MY174000A (en) | Novel pyridine derivatives | |
| MX2016004934A (en) | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy. | |
| MX362879B (en) | Novel uses. | |
| PH12015500585A1 (en) | Modified hyaluronic acid derivatives and use thereof | |
| IN2014DN10669A (en) | ||
| MX363458B (en) | Novel tetrazolone derivatives. | |
| MX365192B (en) | Bendamustine derivatives and related compounds, and medical use thereof cancer therapy. | |
| PH12015500373B1 (en) | Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease | |
| MX2014009084A (en) | Pyrimidooxazocine derivatives as mtor - inhibitors. | |
| TN2013000089A1 (en) | Triazine-oxadiazoles | |
| MA37778A1 (en) | Carbamate / urea derivatives |